Alzheimer’s disease (AD) and Parkinson’s disease (PD) both are distinct forms of dementia. They affect different regions in the cerebrum (or brain). The two neurodegenerative diseases also have discrete genetic and environmental risk factors. However, years of experimental research by neurologists has formulated the hypothesis that the two diseases start to look similar at the […]
drug discovery
Drug Discovery in Academia
Over the past decade there has been increasing pressure on the pharmaceutical industry to increase economic efficiencies in drug discovery. This has been driven by several factors including the increased costs of R&D, lower productivity, patent expiration, generic competition and the increasing difficulty in bringing new chemical entities to market. The extraordinary investment requirements have […]
Demystifying Biomarker Discovery
Proteomics is an emerging field that is frequently used for clinical biomarker discovery. For this article, proteomics is defined as a mass spectrometry-based approach used to identify proteins. The biomarker discovery process is distinct from biomarker validation or the development of a clinical test. The development of a clinical biomarker incurs heavy expenditure and also […]
